ARCHIVES

NCI Places Hold On Genentech Drug Trials, Citing Disagreement Over Intellectual Property Provisions.

This article is from The Cancer Letter archive.

Vol. 36 No. 09 | March 12, 2010

Download PDF Visit The Full Archive

Related Articles

Mayo’s Regional Program – Keys To Success Are Service, Communications

December 9, 1977

FDA Grants Priority Review To Two Drugs in NSCLC

February 22, 2013

In Brief: Eyre ACS President, Freeman President Elects, Kathleen Horsch Chairman, Davis Heads ASTRO

November 20, 1987

Heart Institute Withdraws Sponsorship Of Breast Cancer Prevention Trial

October 27, 1995

Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”

September 30, 2005

FDA Advisors Oppose Group’s Tamoxifen Trial, But Okay The Idea

July 6, 1990